You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
The traditional end-points for clinical studies of lung diseases were based on functional parameters. Their value as surrogate markers for disease activity and progression has been increasingly questioned by scientists, carers, regulatory agencies and funding bodies. Novel tools and methods with regard to biomarkers and patient-reported outcomes have made these parameters emerge from their status as interesting secondary end-points and become potential primary outcomes for clinical trials. Nevertheless, their relevance and validity still needs to be proven. This issue of the European Respiratory Monograph describes the current status regarding end-points in all relevant areas of pulmonary medicine.
Idiopathic pulmonary fibrosis (IPF) is a steadily progressive and ultimately fatal disease of unknown origin. Recent years have seen advances in our understanding of IPF and a number of guidelines have been published. But many questions remain unanswered, particularly surrounding probable versus definite IPF. This Monograph aims to discuss the latest achievements in IPF, and covers key diagnostic issues, staging of the disease, complications and comorbidities, treatment, unmet patient needs and perspectives for the future. This book will be of interest to all clinicians and researchers in this area.
This issue of Clinics in Chest Medicine, guest-edited by Dr. Gerard Criner and Dr. Bartolome Celli, is focused on Chronic Obstructive Pulmonary Disease. Topics discussed in this issue include but are not limited to: COPD Pathogenesis; Epidemiology of COPD; Host, Gender, and Early Life Factors as Risks for COPD; Alpha One Antitrypsin Deficiency; Lung Function Testing; Assessing Symptom Burden; Chest Imaging in the Diagnosis and Assessment of the Patient with COPD; Biomarkers in the Diagnosis and Assessment of COPD; Asthma/COPD Overlap; Multimorbidity in the Patient with COPD; Definition Causes, Pathogenesis, and Consequences of Exacerbations; Treatment of Acute Exacerbations; Prevention of Exacerbations; Bronchodilators; Benefits and Risks of Inhaled Corticosteroids in COPD; Systemic Medications; Smoking Cessation/Vaccinations; Pulmonary Rehabilitation; Oxygen Therapy/Noninvasive Ventilation; and Interventional and Surgical Therapies for COPD.
Viral respiratory tract infections are important and common causes of morbidity and mortality worldwide. In the past two decades, several novel viral respiratory infections have emerged with epidemic potential that threaten global health security. This Monograph aims to provide an up-to-date and comprehensive overview of severe acute respiratory syndrome, Middle East respiratory syndrome and other viral respiratory infections, including seasonal influenza, avian influenza, respiratory syncytial virus and human rhinovirus, through six chapters written by authoritative experts from around the globe.
This issue of Thoracic Surgery Clinics, guest edited by Drs. Virginia R. Litle and Robert J. Canelli, is devoted to Peri-operative Management of the Thoracic Patient. Drs. Litle and Canelli have assembled expert authors to review the following topics: Preoperative Evaluation of Patients Undergoing Thoracic Surgery; Prehab of the Thoracic Patient; Enhanced Recovery after Thoracic Surgery; Surgical Approaches for Esophagectomy: Open, Minimally Invasive, Robotic. What is the Approach Algorithm?; Intraoperative Anesthetic Management of the Thoracic Surgery Patient; Intraoperative Surgical and Anesthetic Concerns for Robotic Approach to the Thoracic Surgery Patient; Prevention of Postoperative Prolonged Air-leak after Pulmonary Resection; Intraoperative Pre-emptive Prevention of Esophagectomy Complications: Role of Feeding Tubes, Pyloric Drainage Procedures, Anastomotic Buttressing; Interventional Pulmonology: A Brave New World; Pain Management in Thoracic Surgery; Management of Complications after Lung Resections; Management of complications after esophagectomy; and more!
Chronic obstructive pulmonary disease (COPD) is one of the most common respiratory diseases that is associated with significant morbidity and mortality worldwide. Exposure to toxic particles and gases, including cigarette smoke, is the main risk factor for COPD. Genetic predisposition also plays a major role, which besides toxic exposure type and duration, can determine different disease phenotypes. Patients with COPD often experience troublesome respiratory symptoms, frequent chest infections, and most importantly, are at risk of serious complications such as lung cancer and cardiorespiratory failure. Despite this, there is currently no cure for COPD, but available treatment options (pharmacological, non-pharmacological, and interventional) can help slow disease progression and improve symptoms and quality of life.
Community-acquired pneumonia remains the leading cause of hospitalisation for infectious disease in Europe, and a major cause of morbidity and mortality. This issue of the European Respiratory Monograph brings together leading experts in pulmonology, infectious diseases and critical care from around the world to present the most recent advances in the management of community-acquired pneumonia. It provides a comprehensive overview of the disease, including chapters on microbiology, pathophysiology, antibiotic therapy and prevention, along with hot topics such as viral pneumonias and pneumonia associated with inhaled corticosteroids.
The lung is the most common site of complications resulting from HIV infection. These respiratory conditions may be of infective or noninfective origin, and are associated with considerable morbidity and mortality. The editors of “Pulmonary Complications of HIV” have brought together experts from around the world to discuss this major area. A broad range of topics is covered, from the global epidemiology of HIV to transplantation, and recent advances in HIV infection, complications, treatment and prevention are discussed. The editors hope that books such as “Pulmonary Complications of HIV” will help us move towards achieving more successful therapies for HIV-related pulmonary infectious diseases.